Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Humanized Type III Collagen for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
NCT07377734Phase 2Recruiting
- Sponsor
- Wang Jianliu
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human type III collagen in endometrial cancer (EC), Atypical endometrial hyperplasia (AEH), sponsored by Wang Jianliu. Started Jan 2026; status: recruiting.
02
Drugs
recombinant human type III collagen
03
Conditions
endometrial cancer (EC)Atypical endometrial hyperplasia (AEH)
Beyond the preview
Go deeper on NCT07377734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377734.